03320.HK
China Resources Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 4.64
+3.11%Oct 30, 2026, 04:24 UTC
China’s National Medical Products Administration approved China Resources Sanjiu Pharmaceutical’s polyethylene glycol 3350 electrolyte oral solution, deeming it to have passed the generic-drug quality and efficacy consistency evaluation.
Source:Oct 22, 2026, 09:40 UTC
China’s National Medical Products Administration approved China Resources Sanjiu’s Yiguanjian granules for marketing.
Source:Oct 21, 2026, 05:59 UTC
China’s National Medical Products Administration issued drug registration certificates for baricitinib tablets and compound potassium phosphate injection to subsidiaries of China Resources Pharmaceutical Group Ltd..
Source:Oct 20, 2026, 01:41 UTC
China Resources Pharmaceutical Group Ltd. said its non-wholly owned subsidiary, China Resources Pharmaceutical Commercial, proposed issuing new shares through a public tender, with the number of shares and proceeds to be determined later.
Source:Oct 20, 2026, 01:37 UTC
China Resources Pharmaceutical Group Ltd. completed a public issuance in China of RMB 900 million in three-year 2026 corporate bonds at an annual coupon rate of 1.48%.
Source:Oct 16, 2026, 08:46 UTC
China’s National Medical Products Administration approved a supplemental drug application for mycophenolate mofetil for injection from China Resources Pharmaceutical Group Ltd., confirming it passed the generic injectable drug consistency evaluation.
Source:Oct 12, 2026, 04:27 UTC
The U.S. Food and Drug Administration authorized China Resources Pharmaceutical Group Ltd. subsidiary Shuanghe Runchuang to conduct clinical trials of DC7001A capsules for systemic lupus erythematosus.
Source:Sep 29, 2026, 04:14 UTC
China Resources Pharmaceutical Group's subsidiary Shuanghe Xiangzhong received approval from the National Medical Products Administration for its brexpiprazole active pharmaceutical ingredient marketing application.
Source:Sep 28, 2026, 08:12 UTC
Changfeng Pharmaceutical shares fell 23.2% to HK$7.29 on 28 September 2026.
Source:Sep 18, 2026, 04:30 UTC
China Resources Pharmaceutical Group's subsidiary China Resources Pharmaceutical Commercial signed a strategic cooperation agreement with Sino Biopharmaceutical covering drug commercialization and distribution, supply chain coordination, drug development, market access, DTP pharmacies and patient disease management, targeting a cooperation scale of RMB 10 billion.
Source:Aug 24, 2026, 08:47 UTC
China Resources Pharmaceutical reported interim results for the six months ended June 2026, with net profit up 5.3% to RMB 2.187 billion and total revenue up nearly 2% to RMB 134.458 billion.
Aug 24, 2026, 08:33 UTC
China Resources Pharmaceutical Group announced an interim dividend of RMB 0.087 per share.
Aug 12, 2026, 07:23 UTC
Hangzhou Bailun Testing Technology, a wholly-owned subsidiary of Baicheng Pharmaceutical, won a procurement contract from Kunming Pharmaceutical Group for gene toxicity impurity assessment services.
Source:Aug 3, 2026, 04:21 UTC
China Resources Pharmaceutical's subsidiary China Resources Jiangzhong Pharmaceutical obtained regulatory approval from China's State Administration for Market Regulation for two new special medical foods, expanding its portfolio to four registered products.
Source:Jul 29, 2026, 13:07 UTC
China Resources Pharmaceutical Group issued the second tranche of 2026 medium-term notes with a principal amount of 1 billion yuan, a three-year term, and an annual coupon rate of 1.52%.
Source:Jul 23, 2026, 01:23 UTC
China Resources Pharmaceutical Group's wholly-owned subsidiary China Resources Pharmaceutical Holdings completed the issuance of 1 billion yuan in medium-term notes with a coupon rate of 1.53%.
Source: